img

Global Myasthenia Gravis Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Myasthenia Gravis Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Myasthenia Gravis Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Myasthenia Gravis Drugs market is projected to reach US$ 2404.4 million in 2034, increasing from US$ 1426 million in 2022, with the CAGR of 7.6% during the period of 2024 to 2034. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Myasthenia Gravis Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Myasthenia Gravis Drugs key manufacturers include Flamel Technologies, F. Hoffmann-La Roche, Grifols, Pfizer, Takeda, Novartis, Bausch Health, Alexion Pharmaceuticals and Catalyst Pharmaceuticals, etc. Flamel Technologies, F. Hoffmann-La Roche, Grifols are top 3 players and held % sales share in total in 2022.
Myasthenia Gravis Drugs can be divided into Anticholinesterases, Immunosuppressants and Intravenous Immune Globulins,, etc. Anticholinesterases is the mainstream product in the market, accounting for % sales share globally in 2022.
Myasthenia Gravis Drugs is widely used in various fields, such as Hospitals and Clinics, etc. Hospitals provides greatest supports to the Myasthenia Gravis Drugs industry development. In 2022, global % sales of Myasthenia Gravis Drugs went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Myasthenia Gravis Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Flamel Technologies
F. Hoffmann-La Roche
Grifols
Pfizer
Takeda
Novartis
Bausch Health
Alexion Pharmaceuticals
Catalyst Pharmaceuticals
CSL
Curavac
Cytokinetics
Galencia
GlaxoSmithKline
Lupin Pharmaceuticals
Mitsubishi Tanabe Pharma
Segment by Type
Anticholinesterases
Immunosuppressants
Intravenous Immune Globulins

Segment by Application


Hospitals
Clinics

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Myasthenia Gravis Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Myasthenia Gravis Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Myasthenia Gravis Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Myasthenia Gravis Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Myasthenia Gravis Drugs introduction, etc. Myasthenia Gravis Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Myasthenia Gravis Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Myasthenia Gravis Drugs Market Overview
1.1 Myasthenia Gravis Drugs Product Overview
1.2 Myasthenia Gravis Drugs Market Segment by Type
1.2.1 Anticholinesterases
1.2.2 Immunosuppressants
1.2.3 Intravenous Immune Globulins
1.3 Global Myasthenia Gravis Drugs Market Size by Type
1.3.1 Global Myasthenia Gravis Drugs Market Size Overview by Type (2018-2034)
1.3.2 Global Myasthenia Gravis Drugs Historic Market Size Review by Type (2018-2024)
1.3.3 Global Myasthenia Gravis Drugs Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Myasthenia Gravis Drugs Sales Breakdown by Type (2018-2024)
1.4.2 Europe Myasthenia Gravis Drugs Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Myasthenia Gravis Drugs Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Myasthenia Gravis Drugs Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Myasthenia Gravis Drugs Sales Breakdown by Type (2018-2024)
2 Global Myasthenia Gravis Drugs Market Competition by Company
2.1 Global Top Players by Myasthenia Gravis Drugs Sales (2018-2024)
2.2 Global Top Players by Myasthenia Gravis Drugs Revenue (2018-2024)
2.3 Global Top Players by Myasthenia Gravis Drugs Price (2018-2024)
2.4 Global Top Manufacturers Myasthenia Gravis Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Myasthenia Gravis Drugs Market Competitive Situation and Trends
2.5.1 Myasthenia Gravis Drugs Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Myasthenia Gravis Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Myasthenia Gravis Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Myasthenia Gravis Drugs Market
2.8 Key Manufacturers Myasthenia Gravis Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Myasthenia Gravis Drugs Status and Outlook by Region
3.1 Global Myasthenia Gravis Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Myasthenia Gravis Drugs Historic Market Size by Region
3.2.1 Global Myasthenia Gravis Drugs Sales in Volume by Region (2018-2024)
3.2.2 Global Myasthenia Gravis Drugs Sales in Value by Region (2018-2024)
3.2.3 Global Myasthenia Gravis Drugs Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Myasthenia Gravis Drugs Forecasted Market Size by Region
3.3.1 Global Myasthenia Gravis Drugs Sales in Volume by Region (2024-2034)
3.3.2 Global Myasthenia Gravis Drugs Sales in Value by Region (2024-2034)
3.3.3 Global Myasthenia Gravis Drugs Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Myasthenia Gravis Drugs by Application
4.1 Myasthenia Gravis Drugs Market Segment by Application
4.1.1 Hospitals
4.1.2 Clinics
4.2 Global Myasthenia Gravis Drugs Market Size by Application
4.2.1 Global Myasthenia Gravis Drugs Market Size Overview by Application (2018-2034)
4.2.2 Global Myasthenia Gravis Drugs Historic Market Size Review by Application (2018-2024)
4.2.3 Global Myasthenia Gravis Drugs Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Myasthenia Gravis Drugs Sales Breakdown by Application (2018-2024)
4.3.2 Europe Myasthenia Gravis Drugs Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Myasthenia Gravis Drugs Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Myasthenia Gravis Drugs Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Myasthenia Gravis Drugs Sales Breakdown by Application (2018-2024)
5 North America Myasthenia Gravis Drugs by Country
5.1 North America Myasthenia Gravis Drugs Historic Market Size by Country
5.1.1 North America Myasthenia Gravis Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Myasthenia Gravis Drugs Sales in Volume by Country (2018-2024)
5.1.3 North America Myasthenia Gravis Drugs Sales in Value by Country (2018-2024)
5.2 North America Myasthenia Gravis Drugs Forecasted Market Size by Country
5.2.1 North America Myasthenia Gravis Drugs Sales in Volume by Country (2024-2034)
5.2.2 North America Myasthenia Gravis Drugs Sales in Value by Country (2024-2034)
6 Europe Myasthenia Gravis Drugs by Country
6.1 Europe Myasthenia Gravis Drugs Historic Market Size by Country
6.1.1 Europe Myasthenia Gravis Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Myasthenia Gravis Drugs Sales in Volume by Country (2018-2024)
6.1.3 Europe Myasthenia Gravis Drugs Sales in Value by Country (2018-2024)
6.2 Europe Myasthenia Gravis Drugs Forecasted Market Size by Country
6.2.1 Europe Myasthenia Gravis Drugs Sales in Volume by Country (2024-2034)
6.2.2 Europe Myasthenia Gravis Drugs Sales in Value by Country (2024-2034)
7 Asia-Pacific Myasthenia Gravis Drugs by Region
7.1 Asia-Pacific Myasthenia Gravis Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Myasthenia Gravis Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Myasthenia Gravis Drugs Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Myasthenia Gravis Drugs Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Myasthenia Gravis Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Myasthenia Gravis Drugs Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Myasthenia Gravis Drugs Sales in Value by Region (2024-2034)
8 Latin America Myasthenia Gravis Drugs by Country
8.1 Latin America Myasthenia Gravis Drugs Historic Market Size by Country
8.1.1 Latin America Myasthenia Gravis Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Myasthenia Gravis Drugs Sales in Volume by Country (2018-2024)
8.1.3 Latin America Myasthenia Gravis Drugs Sales in Value by Country (2018-2024)
8.2 Latin America Myasthenia Gravis Drugs Forecasted Market Size by Country
8.2.1 Latin America Myasthenia Gravis Drugs Sales in Volume by Country (2024-2034)
8.2.2 Latin America Myasthenia Gravis Drugs Sales in Value by Country (2024-2034)
9 Middle East and Africa Myasthenia Gravis Drugs by Country
9.1 Middle East and Africa Myasthenia Gravis Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Myasthenia Gravis Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Myasthenia Gravis Drugs Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Myasthenia Gravis Drugs Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Myasthenia Gravis Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Myasthenia Gravis Drugs Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Myasthenia Gravis Drugs Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Flamel Technologies
10.1.1 Flamel Technologies Company Information
10.1.2 Flamel Technologies Introduction and Business Overview
10.1.3 Flamel Technologies Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Flamel Technologies Myasthenia Gravis Drugs Products Offered
10.1.5 Flamel Technologies Recent Development
10.2 F. Hoffmann-La Roche
10.2.1 F. Hoffmann-La Roche Company Information
10.2.2 F. Hoffmann-La Roche Introduction and Business Overview
10.2.3 F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.2.4 F. Hoffmann-La Roche Myasthenia Gravis Drugs Products Offered
10.2.5 F. Hoffmann-La Roche Recent Development
10.3 Grifols
10.3.1 Grifols Company Information
10.3.2 Grifols Introduction and Business Overview
10.3.3 Grifols Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Grifols Myasthenia Gravis Drugs Products Offered
10.3.5 Grifols Recent Development
10.4 Pfizer
10.4.1 Pfizer Company Information
10.4.2 Pfizer Introduction and Business Overview
10.4.3 Pfizer Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Pfizer Myasthenia Gravis Drugs Products Offered
10.4.5 Pfizer Recent Development
10.5 Takeda
10.5.1 Takeda Company Information
10.5.2 Takeda Introduction and Business Overview
10.5.3 Takeda Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Takeda Myasthenia Gravis Drugs Products Offered
10.5.5 Takeda Recent Development
10.6 Novartis
10.6.1 Novartis Company Information
10.6.2 Novartis Introduction and Business Overview
10.6.3 Novartis Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Novartis Myasthenia Gravis Drugs Products Offered
10.6.5 Novartis Recent Development
10.7 Bausch Health
10.7.1 Bausch Health Company Information
10.7.2 Bausch Health Introduction and Business Overview
10.7.3 Bausch Health Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Bausch Health Myasthenia Gravis Drugs Products Offered
10.7.5 Bausch Health Recent Development
10.8 Alexion Pharmaceuticals
10.8.1 Alexion Pharmaceuticals Company Information
10.8.2 Alexion Pharmaceuticals Introduction and Business Overview
10.8.3 Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Alexion Pharmaceuticals Myasthenia Gravis Drugs Products Offered
10.8.5 Alexion Pharmaceuticals Recent Development
10.9 Catalyst Pharmaceuticals
10.9.1 Catalyst Pharmaceuticals Company Information
10.9.2 Catalyst Pharmaceuticals Introduction and Business Overview
10.9.3 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Products Offered
10.9.5 Catalyst Pharmaceuticals Recent Development
10.10 CSL
10.10.1 CSL Company Information
10.10.2 CSL Introduction and Business Overview
10.10.3 CSL Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.10.4 CSL Myasthenia Gravis Drugs Products Offered
10.10.5 CSL Recent Development
10.11 Curavac
10.11.1 Curavac Company Information
10.11.2 Curavac Introduction and Business Overview
10.11.3 Curavac Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Curavac Myasthenia Gravis Drugs Products Offered
10.11.5 Curavac Recent Development
10.12 Cytokinetics
10.12.1 Cytokinetics Company Information
10.12.2 Cytokinetics Introduction and Business Overview
10.12.3 Cytokinetics Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Cytokinetics Myasthenia Gravis Drugs Products Offered
10.12.5 Cytokinetics Recent Development
10.13 Galencia
10.13.1 Galencia Company Information
10.13.2 Galencia Introduction and Business Overview
10.13.3 Galencia Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.13.4 Galencia Myasthenia Gravis Drugs Products Offered
10.13.5 Galencia Recent Development
10.14 GlaxoSmithKline
10.14.1 GlaxoSmithKline Company Information
10.14.2 GlaxoSmithKline Introduction and Business Overview
10.14.3 GlaxoSmithKline Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.14.4 GlaxoSmithKline Myasthenia Gravis Drugs Products Offered
10.14.5 GlaxoSmithKline Recent Development
10.15 Lupin Pharmaceuticals
10.15.1 Lupin Pharmaceuticals Company Information
10.15.2 Lupin Pharmaceuticals Introduction and Business Overview
10.15.3 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.15.4 Lupin Pharmaceuticals Myasthenia Gravis Drugs Products Offered
10.15.5 Lupin Pharmaceuticals Recent Development
10.16 Mitsubishi Tanabe Pharma
10.16.1 Mitsubishi Tanabe Pharma Company Information
10.16.2 Mitsubishi Tanabe Pharma Introduction and Business Overview
10.16.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales, Revenue and Gross Margin (2018-2024)
10.16.4 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Products Offered
10.16.5 Mitsubishi Tanabe Pharma Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Myasthenia Gravis Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Myasthenia Gravis Drugs Industrial Chain Analysis
11.4 Myasthenia Gravis Drugs Market Dynamics
11.4.1 Myasthenia Gravis Drugs Industry Trends
11.4.2 Myasthenia Gravis Drugs Market Drivers
11.4.3 Myasthenia Gravis Drugs Market Challenges
11.4.4 Myasthenia Gravis Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Myasthenia Gravis Drugs Distributors
12.3 Myasthenia Gravis Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Anticholinesterases
Table 2. Major Company of Immunosuppressants
Table 3. Major Company of Intravenous Immune Globulins
Table 4. Global Myasthenia Gravis Drugs Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Myasthenia Gravis Drugs Sales by Type (2018-2024) & (MT)
Table 6. Global Myasthenia Gravis Drugs Sales Market Share in Volume by Type (2018-2024)
Table 7. Global Myasthenia Gravis Drugs Sales by Type (2018-2024) & (US& Million)
Table 8. Global Myasthenia Gravis Drugs Market Share in Value by Type (2018-2024)
Table 9. Global Myasthenia Gravis Drugs Price by Type (2018-2024) & (USD/Kg)
Table 10. Global Myasthenia Gravis Drugs Sales by Type (2024-2034) & (MT)
Table 11. Global Myasthenia Gravis Drugs Sales Market Share in Volume by Type (2024-2034)
Table 12. Global Myasthenia Gravis Drugs Sales by Type (2024-2034) & (US$ Million)
Table 13. Global Myasthenia Gravis Drugs Sales Market Share in Value by Type (2024-2034)
Table 14. Global Myasthenia Gravis Drugs Price by Type (2024-2034) & (USD/Kg)
Table 15. North America Myasthenia Gravis Drugs Sales by Type (2018-2024) & (MT)
Table 16. North America Myasthenia Gravis Drugs Sales by Type (2018-2024) & (US$ Million)
Table 17. Europe Myasthenia Gravis Drugs Sales (MT) by Type (2018-2024)
Table 18. Europe Myasthenia Gravis Drugs Sales by Type (2018-2024) & (US$ Million)
Table 19. Asia-Pacific Myasthenia Gravis Drugs Sales (MT) by Type (2018-2024)
Table 20. Asia-Pacific Myasthenia Gravis Drugs Sales by Type (2018-2024) & (US$ Million)
Table 21. Latin America Myasthenia Gravis Drugs Sales (MT) by Type (2018-2024)
Table 22. Latin America Myasthenia Gravis Drugs Sales by Type (2018-2024) & (US$ Million)
Table 23. Middle East and Africa Myasthenia Gravis Drugs Sales (MT) by Type (2018-2024)
Table 24. Middle East and Africa Myasthenia Gravis Drugs Sales by Type (2018-2024) & (US$ Million)
Table 25. Global Myasthenia Gravis Drugs Sales by Company (2018-2024) & (MT)
Table 26. Global Myasthenia Gravis Drugs Sales Share by Company (2018-2024)
Table 27. Global Myasthenia Gravis Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 28. Global Myasthenia Gravis Drugs Revenue Share by Company (2018-2024)
Table 29. Global Market Myasthenia Gravis Drugs Price by Company (2018-2024) & (USD/Kg)
Table 30. Global Myasthenia Gravis Drugs Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 31. Global Myasthenia Gravis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 32. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Myasthenia Gravis Drugs as of 2022)
Table 33. Date of Key Manufacturers Enter into Myasthenia Gravis Drugs Market
Table 34. Key Manufacturers Myasthenia Gravis Drugs Product Type
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Myasthenia Gravis Drugs Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 37. Global Myasthenia Gravis Drugs Sales by Region (2018-2024) & (MT)
Table 38. Global Myasthenia Gravis Drugs Sales Market Share in Volume by Region (2018-2024)
Table 39. Global Myasthenia Gravis Drugs Sales by Region (2018-2024) & (US$ Million)
Table 40. Global Myasthenia Gravis Drugs Sales Market Share in Value by Region (2018-2024)
Table 41. Global Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2018-2024)
Table 42. Global Myasthenia Gravis Drugs Sales by Region (2024-2034) & (MT)
Table 43. Global Myasthenia Gravis Drugs Sales Market Share in Volume by Region (2024-2034)
Table 44. Global Myasthenia Gravis Drugs Sales by Region (2024-2034) & (US$ Million)
Table 45. Global Myasthenia Gravis Drugs Sales Market Share in Value by Region (2024-2034)
Table 46. Global Myasthenia Gravis Drugs Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2024-2034)
Table 47. Global Myasthenia Gravis Drugs Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 48. Global Myasthenia Gravis Drugs Sales by Application (2018-2024) & (MT)
Table 49. Global Myasthenia Gravis Drugs Sales Market Share in Volume by Application (2018-2024)
Table 50. Global Myasthenia Gravis Drugs Sales by Application (2018-2024) & (US$ Million)
Table 51. Global Myasthenia Gravis Drugs Sales Market Share in Value by Application (2018-2024)
Table 52. Global Myasthenia Gravis Drugs Price by Application (2018-2024) & (USD/Kg)
Table 53. Global Myasthenia Gravis Drugs Sales by Application (2024-2034) & (MT)
Table 54. Global Myasthenia Gravis Drugs Sales Market Share in Volume by Application (2024-2034)
Table 55. Global Myasthenia Gravis Drugs Sales by Application (2024-2034) & (US$ Million)
Table 56. Global Myasthenia Gravis Drugs Sales Market Share in Value by Application (2024-2034)
Table 57. Global Myasthenia Gravis Drugs Price by Application (2024-2034) & (USD/Kg)
Table 58. North America Myasthenia Gravis Drugs Sales by Application (2018-2024) (MT)
Table 59. North America Myasthenia Gravis Drugs Sales by Application (2018-2024) & (US$ Million)
Table 60. Europe Myasthenia Gravis Drugs Sales by Application (2018-2024) (MT)
Table 61. Europe Myasthenia Gravis Drugs Sales by Application (2018-2024) & (US$ Million)
Table 62. Asia-Pacific Myasthenia Gravis Drugs Sales by Application (2018-2024) (MT)
Table 63. Asia-Pacific Myasthenia Gravis Drugs Sales by Application (2018-2024) & (US$ Million)
Table 64. Latin America Myasthenia Gravis Drugs Sales by Application (2018-2024) (MT)
Table 65. Latin America Myasthenia Gravis Drugs Sales by Application (2018-2024) & (US$ Million)
Table 66. Middle East and Africa Myasthenia Gravis Drugs Sales by Application (2018-2024) (MT)
Table 67. Middle East and Africa Myasthenia Gravis Drugs Sales by Application (2018-2024) & (US$ Million)
Table 68. North America Myasthenia Gravis Drugs Sales by Country (2018-2024) & (MT)
Table 69. North America Myasthenia Gravis Drugs Sales Market Share in Volume by Country (2018-2024)
Table 70. North America Myasthenia Gravis Drugs Sales by Country (2018-2024) & (US$ Million)
Table 71. North America Myasthenia Gravis Drugs Sales Market Share in Value by Country (2018-2024)
Table 72. North America Myasthenia Gravis Drugs Sales by Country (2024-2034) & (MT)
Table 73. North America Myasthenia Gravis Drugs Sales Market Share in Volume by Country (2024-2034)
Table 74. North America Myasthenia Gravis Drugs Sales by Country (2024-2034) & (US$ Million)
Table 75. North America Myasthenia Gravis Drugs Sales Market Share in Value by Country (2024-2034)
Table 76. Europe Myasthenia Gravis Drugs Sales by Country (2018-2024) & (MT)
Table 77. Europe Myasthenia Gravis Drugs Sales Market Share in Volume by Country (2018-2024)
Table 78. Europe Myasthenia Gravis Drugs Sales by Country (2018-2024) & (US$ Million)
Table 79. Europe Myasthenia Gravis Drugs Sales Market Share in Value by Country (2018-2024)
Table 80. Europe Myasthenia Gravis Drugs Sales by Country (2024-2034) & (MT)
Table 81. Europe Myasthenia Gravis Drugs Sales Market Share in Volume by Country (2024-2034)
Table 82. Europe Myasthenia Gravis Drugs Sales by Country (2024-2034) & (US$ Million)
Table 83. Europe Myasthenia Gravis Drugs Sales Market Share in Value by Country (2024-2034)
Table 84. Asia-Pacific Myasthenia Gravis Drugs Sales by Region (2018-2024) & (MT)
Table 85. Asia-Pacific Myasthenia Gravis Drugs Sales Market Share in Volume by Region (2018-2024)
Table 86. Asia-Pacific Myasthenia Gravis Drugs Sales by Region (2018-2024) & (US$ Million)
Table 87. Asia-Pacific Myasthenia Gravis Drugs Sales Market Share in Value by Region (2018-2024)
Table 88. Asia-Pacific Myasthenia Gravis Drugs Sales by Region (2024-2034) & (MT)
Table 89. Asia-Pacific Myasthenia Gravis Drugs Sales Market Share in Volume by Region (2024-2034)
Table 90. Asia-Pacific Myasthenia Gravis Drugs Sales by Region (2024-2034) & (US$ Million)
Table 91. Asia-Pacific Myasthenia Gravis Drugs Sales Market Share in Value by Region (2024-2034)
Table 92. Latin America Myasthenia Gravis Drugs Sales by Country (2018-2024) & (MT)
Table 93. Latin America Myasthenia Gravis Drugs Sales Market Share in Volume by Country (2018-2024)
Table 94. Latin America Myasthenia Gravis Drugs Sales by Country (2018-2024) & (US$ Million)
Table 95. Latin America Myasthenia Gravis Drugs Sales Market Share in Value by Country (2018-2024)
Table 96. Latin America Myasthenia Gravis Drugs Sales by Country (2024-2034) & (MT)
Table 97. Latin America Myasthenia Gravis Drugs Sales Market Share in Volume by Country (2024-2034)
Table 98. Latin America Myasthenia Gravis Drugs Sales by Country (2024-2034) & (US$ Million)
Table 99. Latin America Myasthenia Gravis Drugs Sales Market Share in Value by Country (2024-2034)
Table 100. Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2018-2024) & (MT)
Table 101. Middle East and Africa Myasthenia Gravis Drugs Sales Market Share in Volume by Country (2018-2024)
Table 102. Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2018-2024) & (US$ Million)
Table 103. Middle East and Africa Myasthenia Gravis Drugs Sales Market Share in Value by Country (2018-2024)
Table 104. Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2024-2034) & (MT)
Table 105. Middle East and Africa Myasthenia Gravis Drugs Sales Market Share in Volume by Country (2024-2034)
Table 106. Middle East and Africa Myasthenia Gravis Drugs Sales by Country (2024-2034) & (US$ Million)
Table 107. Middle East and Africa Myasthenia Gravis Drugs Sales Market Share in Value by Country (2024-2034)
Table 108. Flamel Technologies Company Information
Table 109. Flamel Technologies Introduction and Business Overview
Table 110. Flamel Technologies Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 111. Flamel Technologies Myasthenia Gravis Drugs Product
Table 112. Flamel Technologies Recent Development
Table 113. F. Hoffmann-La Roche Company Information
Table 114. F. Hoffmann-La Roche Introduction and Business Overview
Table 115. F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 116. F. Hoffmann-La Roche Myasthenia Gravis Drugs Product
Table 117. F. Hoffmann-La Roche Recent Development
Table 118. Grifols Company Information
Table 119. Grifols Introduction and Business Overview
Table 120. Grifols Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 121. Grifols Myasthenia Gravis Drugs Product
Table 122. Grifols Recent Development
Table 123. Pfizer Company Information
Table 124. Pfizer Introduction and Business Overview
Table 125. Pfizer Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 126. Pfizer Myasthenia Gravis Drugs Product
Table 127. Pfizer Recent Development
Table 128. Takeda Company Information
Table 129. Takeda Introduction and Business Overview
Table 130. Takeda Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 131. Takeda Myasthenia Gravis Drugs Product
Table 132. Takeda Recent Development
Table 133. Novartis Company Information
Table 134. Novartis Introduction and Business Overview
Table 135. Novartis Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 136. Novartis Myasthenia Gravis Drugs Product
Table 137. Novartis Recent Development
Table 138. Bausch Health Company Information
Table 139. Bausch Health Introduction and Business Overview
Table 140. Bausch Health Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 141. Bausch Health Myasthenia Gravis Drugs Product
Table 142. Bausch Health Recent Development
Table 143. Alexion Pharmaceuticals Company Information
Table 144. Alexion Pharmaceuticals Introduction and Business Overview
Table 145. Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 146. Alexion Pharmaceuticals Myasthenia Gravis Drugs Product
Table 147. Alexion Pharmaceuticals Recent Development
Table 148. Catalyst Pharmaceuticals Company Information
Table 149. Catalyst Pharmaceuticals Introduction and Business Overview
Table 150. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 151. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Product
Table 152. Catalyst Pharmaceuticals Recent Development
Table 153. CSL Company Information
Table 154. CSL Introduction and Business Overview
Table 155. CSL Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 156. CSL Myasthenia Gravis Drugs Product
Table 157. CSL Recent Development
Table 158. Curavac Company Information
Table 159. Curavac Introduction and Business Overview
Table 160. Curavac Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 161. Curavac Myasthenia Gravis Drugs Product
Table 162. Curavac Recent Development
Table 163. Cytokinetics Company Information
Table 164. Cytokinetics Introduction and Business Overview
Table 165. Cytokinetics Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 166. Cytokinetics Myasthenia Gravis Drugs Product
Table 167. Cytokinetics Recent Development
Table 168. Galencia Company Information
Table 169. Galencia Introduction and Business Overview
Table 170. Galencia Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 171. Galencia Myasthenia Gravis Drugs Product
Table 172. Galencia Recent Development
Table 173. GlaxoSmithKline Company Information
Table 174. GlaxoSmithKline Introduction and Business Overview
Table 175. GlaxoSmithKline Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 176. GlaxoSmithKline Myasthenia Gravis Drugs Product
Table 177. GlaxoSmithKline Recent Development
Table 178. Lupin Pharmaceuticals Company Information
Table 179. Lupin Pharmaceuticals Introduction and Business Overview
Table 180. Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 181. Lupin Pharmaceuticals Myasthenia Gravis Drugs Product
Table 182. Lupin Pharmaceuticals Recent Development
Table 183. Mitsubishi Tanabe Pharma Company Information
Table 184. Mitsubishi Tanabe Pharma Introduction and Business Overview
Table 185. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2018-2024)
Table 186. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product
Table 187. Mitsubishi Tanabe Pharma Recent Development
Table 188. Key Raw Materials Lists
Table 189. Raw Materials Key Suppliers Lists
Table 190. Myasthenia Gravis Drugs Market Trends
Table 191. Myasthenia Gravis Drugs Market Drivers
Table 192. Myasthenia Gravis Drugs Market Challenges
Table 193. Myasthenia Gravis Drugs Market Restraints
Table 194. Myasthenia Gravis Drugs Distributors List
Table 195. Myasthenia Gravis Drugs Downstream Customers
Table 196. Research Programs/Design for This Report
Table 197. Key Data Information from Secondary Sources
Table 198. Key Data Information from Primary Sources
List of Figures
Figure 1. Myasthenia Gravis Drugs Product Picture
Figure 2. Global Myasthenia Gravis Drugs Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Myasthenia Gravis Drugs Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Myasthenia Gravis Drugs Sales Status and Outlook (2018-2034) & (MT)
Figure 5. Product Picture of Anticholinesterases
Figure 6. Global Anticholinesterases Sales YoY Growth (2018-2034) & (MT)
Figure 7. Product Picture of Immunosuppressants
Figure 8. Global Immunosuppressants Sales YoY Growth (2018-2034) & (MT)
Figure 9. Product Picture of Intravenous Immune Globulins
Figure 10. Global Intravenous Immune Globulins Sales YoY Growth (2018-2034) & (MT)
Figure 11. Global Myasthenia Gravis Drugs Sales by Type (2018-2034) & (US$ Million)
Figure 12. Global Myasthenia Gravis Drugs Sales Market Share by Type in 2022 & 2034
Figure 13. North America Myasthenia Gravis Drugs Sales Market Share in Volume by Type in 2022
Figure 14. North America Myasthenia Gravis Drugs Sales Market Share in Value by Type in 2022
Figure 15. Europe Myasthenia Gravis Drugs Sales Market Share in Volume by Type in 2022
Figure 16. Europe Myasthenia Gravis Drugs Sales Market Share in Value by Type in 2022
Figure 17. Asia-Pacific Myasthenia Gravis Drugs Sales Market Share in Volume by Type in 2022
Figure 18. Asia-Pacific Myasthenia Gravis Drugs Sales Market Share in Value by Type in 2022
Figure 19. Latin America Myasthenia Gravis Drugs Sales Market Share in Volume by Type in 2022
Figure 20. Latin America Myasthenia Gravis Drugs Sales Market Share in Value by Type in 2022
Figure 21. Middle East and Africa Myasthenia Gravis Drugs Sales Market Share in Volume by Type in 2022
Figure 22. Middle East and Africa Myasthenia Gravis Drugs Sales Market Share in Value by Type in 2022
Figure 23. The 5 and 10 Largest Manufacturers in the World: Market Share by Myasthenia Gravis Drugs Sales in 2022
Figure 24. The 5 and 10 Largest Manufacturers in the World: Market Share by Myasthenia Gravis Drugs Revenue in 2022
Figure 25. Myasthenia Gravis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 26. Product Picture of Hospitals
Figure 27. Global Hospitals Sales YoY Growth (2018-2034) & (MT)
Figure 28. Product Picture of Clinics
Figure 29. Global Clinics Sales YoY Growth (2018-2034) & (MT)
Figure 30. Global Myasthenia Gravis Drugs Sales by Application (2018-2034) & (US$ Million)
Figure 31. Global Myasthenia Gravis Drugs Sales Market Share by Application in 2022 & 2034
Figure 32. North America Myasthenia Gravis Drugs Sales Market Share in Volume by Application in 2022
Figure 33. North America Myasthenia Gravis Drugs Sales Market Share in Value by Application in 2022
Figure 34. Europe Myasthenia Gravis Drugs Sales Market Share in Volume by Application in 2022
Figure 35. Europe Myasthenia Gravis Drugs Sales Market Share in Value by Application in 2022
Figure 36. Asia-Pacific Myasthenia Gravis Drugs Sales Market Share in Volume by Application in 2022
Figure 37. Asia-Pacific Myasthenia Gravis Drugs Sales Market Share in Value by Application in 2022
Figure 38. Latin America Myasthenia Gravis Drugs Sales Market Share in Volume by Application in 2022
Figure 39. Latin America Myasthenia Gravis Drugs Sales Market Share in Value by Application in 2022
Figure 40. Middle East and Africa Myasthenia Gravis Drugs Sales Market Share in Value by Application in 2022
Figure 41. Key Raw Materials Price
Figure 42. Myasthenia Gravis Drugs Manufacturing Cost Structure
Figure 43. Myasthenia Gravis Drugs Industrial Chain Analysis
Figure 44. Channels of Distribution
Figure 45. Distributors Profiles
Figure 46. Bottom-up and Top-down Approaches for This Report
Figure 47. Data Triangulation
Figure 48. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries